BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 24949545)

  • 1. Nomogram to predict recurrence in patients with early- and advanced-stage mucinous and serous borderline ovarian tumors.
    Bendifallah S; Ballester M; Uzan C; Fauvet R; Morice P; Darai E
    Am J Obstet Gynecol; 2014 Dec; 211(6):637.e1-6. PubMed ID: 24949545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nomogram to predict live birth rate after fertility-sparing surgery for borderline ovarian tumours.
    Ouldamer L; Bendifallah S; Naoura I; Body G; Uzan C; Morice P; Ballester M; Daraï E
    Hum Reprod; 2016 Aug; 31(8):1732-7. PubMed ID: 27496944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nomogram to predict the probability of relapse in patients diagnosed with borderline ovarian tumors.
    Obermair A; Tang A; Kondalsamy-Chennakesavan S; Ngan H; Zusterzeel P; Quinn M; Carter J; Leung Y; Janda M
    Int J Gynecol Cancer; 2013 Feb; 23(2):264-7. PubMed ID: 23295940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of clinicopathologic and surgical factors on relapse and pregnancy in young patients (≤40 years old) with borderline ovarian tumors.
    Fang C; Zhao L; Chen X; Yu A; Xia L; Zhang P
    BMC Cancer; 2018 Nov; 18(1):1147. PubMed ID: 30463533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer.
    Barlin JN; Yu C; Hill EK; Zivanovic O; Kolev V; Levine DA; Sonoda Y; Abu-Rustum NR; Huh J; Barakat RR; Kattan MW; Chi DS
    Gynecol Oncol; 2012 Apr; 125(1):25-30. PubMed ID: 22155261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?
    Kajiyama H; Mizuno M; Shibata K; Umezu T; Suzuki S; Yamamoto E; Mitsui H; Sekiya R; Niimi K; Kawai M; Nagasaka T; Kikkawa F
    Eur J Obstet Gynecol Reprod Biol; 2014 Oct; 181():305-10. PubMed ID: 25203309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Borderline ovarian tumors: French guidelines from the CNGOF. Part 2. Surgical management, follow-up, hormone replacement therapy, fertility management and preservation.
    Bourdel N; Huchon C; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; D'argent Mathieu E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
    J Gynecol Obstet Hum Reprod; 2021 Jan; 50(1):101966. PubMed ID: 33144266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinicopathologic analysis of 130 cases of mucinous borderline ovarian tumors].
    Cao DY; Shen K; Tao T; Yang JX; Xiang Y; Huang HF; Wu M; Pan LY; Lang JH
    Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):15-8. PubMed ID: 21429428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel nomogram based on LODDS to predict the prognosis of epithelial ovarian cancer.
    Xu XL; Cheng H; Tang MS; Zhang HL; Wu RY; Yu Y; Li X; Wang XM; Mai J; Yang CL; Jiao L; Li ZL; Zhong ZM; Deng R; Li JD; Zhu XF
    Oncotarget; 2017 Jan; 8(5):8120-8130. PubMed ID: 28042955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Therapeutic Management of Early Stages].
    Canlorbe G; Lecointre L; Chauvet P; Azaïs H; Fauvet R; Uzan C
    Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):287-303. PubMed ID: 32004786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment and verification of the nomogram that predicts the 3-year recurrence risk of epithelial ovarian carcinoma.
    Hu J; Jiao X; Zhu L; Guo H; Wu Y
    BMC Cancer; 2020 Sep; 20(1):938. PubMed ID: 32993522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of laparoscopic fertility-sparing surgery in clinically early-stage epithelial ovarian cancer.
    Park JY; Heo EJ; Lee JW; Lee YY; Kim TJ; Kim BG; Bae DS
    J Gynecol Oncol; 2016 Mar; 27(2):e20. PubMed ID: 26768783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [External multicentric validation of two scores predicting the risk of relapse in patients with borderline ovarian tumors: The nomogram of Bendifallah and the score of Ouldamer].
    Pais P; Huchon C; Chevrot A; Cohen J; Fauconnier A; Rouzier R; Mimouni M
    Bull Cancer; 2017 Sep; 104(9):721-726. PubMed ID: 28778341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk.
    Vasconcelos I; de Sousa Mendes M
    Eur J Cancer; 2015 Mar; 51(5):620-31. PubMed ID: 25661104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder.
    Karakiewicz PI; Shariat SF; Palapattu GS; Gilad AE; Lotan Y; Rogers CG; Vazina A; Gupta A; Bastian PJ; Perrotte P; Sagalowsky AI; Schoenberg M; Lerner SP
    J Urol; 2006 Oct; 176(4 Pt 1):1354-61; discussion 1361-2. PubMed ID: 16952631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of borderline ovarian tumours.
    Gershenson DM
    Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():49-59. PubMed ID: 27780698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Epidemiology and Risk Factors of Relapse, Follow-up and Interest of a Completion Surgery].
    Margueritte F; Sallee C; Lacorre A; Gauroy E; Larouzee E; Chereau E; De La Motte Rouge T; Koskas M; Gauthier T
    Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):248-259. PubMed ID: 32004784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncofertility in patients with stage I epithelial ovarian cancer: fertility-sparing surgery in young women of reproductive age.
    Jiang X; Yang J; Yu M; Xie W; Cao D; Wu M; Pan L; Huang H; You Y; Shen K
    World J Surg Oncol; 2017 Aug; 15(1):154. PubMed ID: 28806962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective evaluation of borderline ovarian tumors: single center experience of 183 cases.
    Gungor T; Cetinkaya N; Yalcin H; Ozdal B; Ozgu E; Baser E; Uygur D; Caglar M; Sirvan L; Erkaya S
    Arch Gynecol Obstet; 2015 Jan; 291(1):123-30. PubMed ID: 25047273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.
    Previs RA; Bevis KS; Huh W; Tillmanns T; Perry L; Moore K; Chapman J; McClung C; Kiet T; Java J; Chan J; Secord AA
    Gynecol Oncol; 2014 Mar; 132(3):531-6. PubMed ID: 24472410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.